Italy investigates Sephora and Benefit over skincare marketing to children
Italy’s competition authority said the LVMH-owned cosmetic brands Sephora and Benefit used an “insidious marketing strategy” to appeal to tween consumers.
1.4 million filers face tax refund delays amid IRS paper check phaseout
Many filers are facing tax refund delays amid the IRS push to phase out paper checks. Here’s what to know if you receive a CP53E notice.
Economist Nouriel Roubini: Trump is likely to escalate the Iran war — risking ‘1970s stagflation’
The economist and investor, known for calling the 2008 financial crisis, also said the “damage has already been done” to the economy.
Gulf markets are splintering as the Iran war continues. Here’s what to know
Investors are grappling with sharp divergence across the Gulf’s markets, as the Iran conflict drives asset volatility in the region.
Sony hikes PS5 prices by up to $150 citing ‘pressures’ in global economy
Sony, like other console makers, is contending with surging memory chip prices which have forced the company to raise prices.
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
Elon Musk’s Grok ordered to stop creating AI nudes by Dutch court as legal pressure mounts
A Dutch court issued a $115,000 penalty for every day xAI fails to remove non-consensual AI-generated nude images created by its chatbot Grok.
The Tech Download: How Russia could profit from Iran war helium supply chain disruption in the chip sector
Helium has emerged as a key focus for the tech sector as industry watchers cast their minds to the implications of a prolonged Iran war.
‘All bets are off’: European borrowing costs hit 15-year highs as investors brace for rate hikes
Bonds issued by various European countries continued to sell off on Friday, deepening a rout that has been mostly continuous since the U.S.-Iran war began.
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
